Smith & Nephew drops guidance as surgical procedures stop amid pandemic

Underlying revenue growth in the quarter to March is expected to drop 8% on 2019

Smith & Nephew

Smith & Nephew PLC (LON:SN.) has withdrawn guidance for 2020 as surgical procedures in the US and Europe are coming to a halt.

In China, which contributed more than half of group organic growth last year, hospital activity had restarted but remains “considerably below” pre-outbreak levels. 

READ: Analysts mull Smith & Nephew's big coronavirus assumptions

The medical products manufacturer said underlying revenue growth in the quarter to March is expected to drop 8% on 2019.

Second quarter revenue and first-half trading margin are estimated to come in “substantially down” compared to last year.

As of 31 December, net debt was US$1.6bn, with committed facilities of US$2.9bn plus another US$550mln in senior notes to be drawn in June.

Shares dropped 3% to 1,389.5p on Monday morning.

--Adds shares--


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



4D Pharma PLC about to start dosing patients in its Phase II trial for COVID-19

4D pharma plc's (LON:DDDD) Duncan Peyton tells Proactive London's Andrew Scott they're focused on live biotherapeutics - a new class of therapeutics which uses bacteria as drugs. ''Even though it's a new area we've made a lot of progress in the five years we've been going ... we've got our...

1 day ago

2 min read